Introduction
Hematopoietic cell transplantation (HCT) is being increasingly used for the treatment of a variety of malignant and nonmalignant disorders. Although considerable advances have been made in transplant techniques and supportive care, HCT can still be associated with considerable shortterm and long-term morbidity and mortality. Iron overload, primarily because of RBC transfusions, is a relatively common but often neglected transplant related complication. This review will discuss the epidemiology, diagnosis, immediate and long-term effects, and treatment options for HCT related iron overload.
Iron homeostasis
Iron is a physiologically essential element because of its ability to readily accept and donate electrons (between Fe 2 þ and Fe 3 þ forms) and plays a key role in several biochemical reactions involving oxygen transport and electron transfer. 1, 2 However, it can also mediate the conversion of hydrogen peroxide to highly toxic free radicals that can lead to tissue damage by oxidation of proteins, peroxidation of membrane lipids and modification of nucleic acids. 1, 3 Tissue damage is clinically most evident in the heart and the liver, where excessive iron deposition leads to organ dysfunction and ultimately, fibrosis.
Systemic and cellular iron balance is very tightly regulated in the human body.
2,3 Around 1-2 mg of iron is absorbed from diet every day. Iron circulates in plasma bound to transferrin, and in the balanced state, there is no circulating free iron. The majority of iron (B60-70%) is incorporated into Hb in RBC whereas the rest is stored in hepatocytes, myoglobin and reticuloendothelial macrophages. Approximately 1-2 mg of iron is lost daily from the skin and the intestine and, in women, through menstruation. Humans do not have any physiological mechanisms to excrete excess iron and iron homeostasis is primarily regulated at the level of iron absorption by regulatory effectors such as hepcidin. 3, 4 In conditions of iron excess, hepcidin levels increase and inhibit intestinal absorption and release of storage iron, whereas its expression is markedly decreased in iron-deficiency states. 1 The function of hepcidin is thought to be further regulated by the HFE protein. 1 Compared to the small amount absorbed from diet, one RBC unit contains 200-250 mg of iron and significant iron accumulation can occur after 10-20 RBC transfusions.
2,5
Iron overload in transfusion-dependent anemias Children with transfusion-dependent anemias, such as thalassemia and sickle-cell disease, frequently develop iron overload due to RBC transfusions. [6] [7] [8] Ineffective erythropoiesis and hemolysis also contribute to iron overload by stimulating the body's regulatory mechanisms to inadvertently increase intestinal absorption of iron. Tissue iron accumulation leads to progressive dysfunction of the heart, liver and endocrine glands. Prior to the introduction of ironchelation therapy, iron overload associated cardiomyopathy and liver fibrosis were among the leading causes of death among children with thalassemia. 9, 10 The rate and amount of tissue iron accumulation are the two most important factors that determine the risk of iron-related organ toxicity. In patients who are receiving regular transfusions but no chelation therapy, tissue iron deposition can begin within 1-2 years, but clinically evident cardiac or hepatic dysfunction may not occur till 10 or more years from initiation of transfusion therapy. 5, 7 End-organ damage can occur earlier in patients with other risk factors such as alcohol and viral hepatitis. Body iron burdens greater than 15 mg per gram liver, dry weight, are associated with an increased risk of cardiac disease and early death whereas levels between 7-15 mg per gram enhance the risk of hepatic fibrosis and endocrine complications. 5, 7 Organ damage typically does not occur with levels less than 7 mg per gram, which for comparison purposes, are similar to those seen in heterozygotes for hereditary hemochromatosis (3-7 mg per gram, dry weight). 7 Although serum ferritin is not as reliable as liver iron concentration (LIC) for estimating body iron stores, the risk of cardiac disease and early death is increased in patients with serum ferritin of more than 2500 ng/ml. 10 Children with thalassemia who have not received adequate iron chelation are also prone to developing and dying from infections. 11, 12 Iron is an essential cofactor for the growth of a number of opportunistic bacteria and fungi and free iron can also increase susceptibility to infections by inhibition of chemotaxis and phagocytosis and impairment of cellular immunity. 13 Estimation of LIC by liver biopsy or imaging is recommended after 1 year of regular transfusions to determine the need for iron-chelation therapy. 5 Iron chelation is initiated once LIC rises above 3 mg per gram, dry weight, and is used to maintain levels between 3-7 mg per gram. However, in clinical practice, clinicians often initiate iron-chelation therapy in regularly transfused children who have elevated serum ferritin levels.
Assessment of body iron stores
Commonly used tests for assessing body iron stores are summarized in Table 1 . Measurement of hepatic iron stores provides the most reliable estimate of body iron burden. 14 Liver biopsy with estimation of LIC (reported commonly as mg iron per gram liver, dry weight) is considered to be the reference method for measuring hepatic iron stores. 5 Although it is an invasive procedure and may not be safely administered in patients with very low platelet counts, a liver biopsy can be advantageous in some HCT recipients because it can also exclude alternative causes of hepatic dysfunction such as infections and GVHD and further guide treatment decisions. [15] [16] [17] Liver biopsy using a transjugular approach is an alternative to percutaneous biopsy. 18 Biomagnetic susceptometry using superconducting quantum interference device utilizes the magnetic property of iron in ferritin and hemosiderin to estimate hepatic iron stores and is considered to be the noninvasive reference standard for estimation of LIC and has an excellent correlation with liver biopsy. 19, 20 However, widespread clinical use has been limited by its cost, complexity and very limited availability (four sites worldwide). A variety of other noninvasive imaging techniques such as magnetic resonance imaging (MRI) have been investigated for measurement of LIC. Liver iron assessment using older MRI techniques and equipment showed variable correlation with liver biopsy estimates of LIC. However more recent MRI techniques such as T2 and R2 MRI have been shown to be reproducible, sensitive and specific methods for noninvasive estimation of LIC. [21] [22] [23] [24] [25] There is no reliable serum or plasma marker for body iron burden. Serum ferritin is commonly used for an indirect estimation of body iron stores. Although sensitive, it is not specific for iron overload as it can be elevated in a variety of infectious and inflammatory states. It also has a poor correlation with LIC and does not reliably predict hepatic iron stores in an individual patient. 7, 8, [26] [27] [28] Infections and GVHD frequently occur in HCT recipients, which can further decrease the sensitivity and specificity of ferritin for diagnosing iron overload. We have observed ferritin to be moderately correlated with LIC in HCT survivors with iron overload. 29 However, ferritin is a good screening test and clinically significant iron overload (LIC47 mg per gram) is uncommon in patients with serum ferritin levels less than 1000 ng/ml. Estimation of LIC should be strongly considered in patients with an elevated ferritin to get a more accurate assessment of body iron burden. Liver biopsy is generally safe and allows for the evaluation of hepatic abnormalities other than iron overload. Recently, MRI has also been reported to be a reliable Table 1 Tests for assessment of body iron stores in HCT recipients 
29-31
Iron overload in HCT HCT recipients, both allogeneic and autologous, are at risk for developing iron overload because of exposure to RBC transfusions, both during the initial treatment of their disease and in the post transplant period (Figure 1 ). The presence of other conditions that alter iron homeostasis, such as carrier state for hereditary hemochromatosis, can amplify this risk. Even in patients who do not need transfusions, a predictable increase in serum iron, transferrin saturation, ferritin and nontransferrin-bound iron has been observed early post transplantation. [32] [33] [34] Besides iron from RBC transfusions, other mechanisms could contribute to the disruption of normal iron homeostasis such as inhibition of erythropoiesis and release of iron from the bone marrow and liver due to cell damage from conditioning regimen toxicity. 35 In patients undergoing HCT for diseases other than thalassemia, iron overload has been reported both early and late post transplant. Most previously reported studies have used variable serum ferritin values to define iron overload or are limited to case series. 17, [36] [37] [38] [39] [40] Contemporary studies have used the more reliable measurement of LIC to define iron overload. Altes et al. 41 reviewed liver samples obtained on autopsy in 59 recipients of autologous and allogeneic HCT. The median LIC was 7.7 mg per gram, dry weight, and LIC of 45.6 mg per gram was present in 40% patients. In a cross-sectional study in allogeneic HCT survivors (median followup 9 years) conducted by Rose et al., 30 38/65 (58%) patients had above normal ferritin. Increased LIC (median 117 mmol/g (B6.5 mg per gram), dry weight) was seen in 31/32 patients with elevated ferritin who underwent a T2* MRI of the liver. In a cross-sectional study that we conducted, 19/56 allogeneic HCT survivors (median followup 2.5 years) had ferritin 41000 ng/ml. 29 Of these, 18 (32%) had elevated LIC (median 7 mg per gram, dry weight) on R2 MRI of the liver; LIC45 mg per gram was present in 13 (23%) patients.
Iron overload and transplant complications
Early and late complications of HCT that have been associated with iron overload are summarized in Table 2 .
A variety of early post transplant complications including infections, liver function test abnormalities and hepatic sinusoidal obstruction syndrome have been attributed to iron overload. 40, 41, 46, 47 There are also emerging data from retrospective studies that pretransplant hyperferritinemia can significantly increase the risk of early nonrelapse mortality after allogeneic and autologous HCT. 36, [50] [51] [52] [53] [54] Free iron can lead to a pro-oxidant state by generating free radicals which could subsequently cause tissue injury and increase the risk of transplant related complications. However, ferritin does not reliably predict body iron stores and the contribution of iron overload to early morbidity and mortality needs to be confirmed in prospective studies.
The late morbidity of iron overload is primarily due to involvement of the heart and liver. Although iron-related liver function test abnormalities have been reported, 16, 17, 29, 39 there are no studies that describe the role of iron overload in late-onset cardiomyopathy and hepatic fibrosis and cirrhosis in patients transplanted for diseases other than thalassemia. In children with thalassemia who have undergone an allogeneic HCT, post transplant irondepletion therapy has been shown to reverse hepatic fibrosis and cardiomyopathy. [55] [56] [57] Iron overload has been reported to increase the risk of infections late after transplantation. 42, 44 The impact of iron overload on longterm nonrelapse mortality has not been investigated.
Treatment of iron overload after HCT
Decisions regarding management of iron overload should be individualized and based on a review of several factors including the need for ongoing RBC transfusion therapy, time since transplantation, ability to tolerate iron-depleting therapy and urgency to reduce body iron stores. For example, coexisting anemia can preclude the use of phlebotomy whereas renal impairment might increase the risk of toxicity from iron-chelating drugs. Also, depletion of iron stores would be more imperative in patients with iron overload related liver test abnormalities or cardiac dysfunction compared to those without these end-organ toxicities.
Iron related end-organ damage is dependent on the rate of iron accumulation and the duration of exposure to elevated iron levels. HCT recipients frequently receive RBC transfusions during the treatment of their underlying hematological disorder and in the early post transplant period. However, unlike children with thalassemia or sickle cell disease, most HCT recipients eventually become transfusion independent. A gradual decline in liver iron stores has been reported in a select subgroup of children with thalassemia with no hepatomegaly or hepatic fibrosis and adequate pretransplant chelation therapy who were treated with allogeneic HCT and became transfusion independent. 58 Although there are no data for the natural evolution of iron overload following transplantation for disorders other than thalassemia, selected transfusionindependent HCT survivors with mild iron overload (LIC less than 5-7 mg per gram liver, dry weight) and no ironrelated organ toxicity can be observed without treatment.
There is no evidence regarding the benefit of depleting excess iron stores on long-term morbidity and mortality in recipients of HCT for diseases other than thalassemia. Children cured of their thalassemia after allogeneic HCT, but with moderate to severe liver iron deposition pretransplant, tend to have persistently elevated hepatic iron levels till more than 5 years after transplantation. 58 Based on this observation, phlebotomy or iron-chelation therapy can be considered in HCT survivors with LIC of more than 7 mg per gram and in those with suspected or proven ironrelated hepatic or cardiac dysfunction, till further data about the natural evolution of post transplant iron overload becomes available.
Although published recommendations for screening and prevention of late effects of transplantation suggest checking a serum ferritin at 1-year post transplant, 59 there are no clear-cut guidelines for when to screen and initiate therapy for iron overload. In thalassemia patients with very high hepatic iron levels, both phlebotomy and deferoxamine have been reported to be feasible and safe within the first few months post transplant. [60] [61] [62] In patients undergoing transplantation for other diseases, a similar degree of iron overload would not be commonly expected. As ironrelated organ damage can take many years to develop, there is no disadvantage in waiting till 1-2 years post transplant before screening patients for iron overload. Earlier screening is indicated in patients with suspected iron-related organ damage (for example, unexplained elevation of liver function tests). There are emerging data that iron overload might increase the risk of early nonrelapse mortality. 36 If this is confirmed in further studies, screening and treatment of iron overload might have to be considered in the pretransplant and early post transplant period.
Treatment options for iron overload in HCT recipients are summarized in Table 3 . Phlebotomy is the treatment of choice for treating iron overload following HCT. Many studies have documented its feasibility and efficacy, both early and late post transplantation. 14, 16, 17, 63 Patients with coexisting anemia may not be able to undergo phlebotomy. Although the use of erythropoiesis stimulating agents to enable phlebotomy has been reported following HCT, 16, 64 caution should be exercised in their use because of recent reports of an increased risk of adverse events such as thromboembolism. 65, 66 Patients not eligible for phlebotomy can be treated with iron chelators. Deferoxamine (Desferal, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) has a proven track record of efficacy and safety with decades of experience and has also been studied in HCT recipients. 61, 62 However, it has to be administered as a prolonged daily s.c. infusion, which often leads to poor compliance. Deferiprone is an oral iron chelator, but is not commercially available in all countries, including in the United States of America, and has not been investigated in HCT recipients. Deferasirox (Exjade, Novartis Pharmaceuticals Corporation) is a recently introduced oral iron chelator with efficacy similar to deferoxamine. [67] [68] [69] Commonly reported side effects include skin rash, nausea, vomiting and diarrhea and elevations in serum creatinine levels. More experience with its use in HCT recipients is also needed.
Unanswered questions
There remain a number of unanswered questions about the short-term and long-term impact of iron overload in recipients of HCT for diseases other than thalassemia. The availability of an oral iron chelator, deferasirox, has simplified the treatment of iron overload and there has been an increasing interest in the investigation of iron and its effect on morbidity and mortality following transplantation. The current paradigm of managing post transplant iron overload is based on extensive experience in children with transfusion-dependent anemias. However, as indicated above, there is an important difference between the two patient populations-in comparison to the latter who need regular transfusion support, transplant recipients generally receive transfusions over a short period of time and then become transfusion independent. The natural evolution of post transplant iron overload has not been well documented and needs to be further investigated. A better understanding of the contribution of iron overload on late effects of transplantation is also needed. Hepatic, endocrine and cardiac late effects are relatively rare and take many years to develop and collaborative multi-institutional efforts will be needed to better evaluate any such associations. The relationship between iron overload and GVHD also needs to be further elucidated. Iron might increase the risk of acute and chronic GVHD through its tendency to cause direct organ toxicity; alternatively, it might decrease the risk of GVHD through its ability to impair host immune responses. The emerging data regarding hyperferritinemia and increase in the risk of early nonrelapse mortality also needs to be confirmed by studies that examine hepatic iron stores because ferritin is a poor predictor of body iron burden.
Conclusions
Iron overload is relatively common in HCT survivors. Serum ferritin is a good screening test, but does not reliably predict body iron stores in an individual patient and estimation of hepatic iron concentration using liver biopsy or MRI should be considered before initiating therapy for iron overload. A subset of patients with mild iron overload and no evidence of end-organ damage can be observed. For patients who need treatment, phlebotomy is the treatment of choice. If coexisting anemia prohibits phlebotomy, ironchelating therapy can be used. More studies are needed to better define the natural history of iron overload and its impact on late morbidity and mortality in transplant recipients.
